ArTS Archivio della ricerca di Trieste

MACOR, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 23.205
EU - Europa 17.981
AS - Asia 15.065
SA - Sud America 5.142
AF - Africa 648
OC - Oceania 409
Continente sconosciuto - Info sul continente non disponibili 20
Totale 62.470
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.960
CN - Cina 5.328
IT - Italia 5.035
BR - Brasile 3.048
PL - Polonia 2.131
DE - Germania 1.727
ES - Italia 1.587
SG - Singapore 1.571
MX - Messico 1.306
GB - Regno Unito 1.201
JP - Giappone 1.184
IN - India 1.105
FR - Francia 1.078
TR - Turchia 966
VN - Vietnam 784
ID - Indonesia 770
CA - Canada 700
SE - Svezia 689
HK - Hong Kong 684
NL - Olanda 562
CO - Colombia 490
PT - Portogallo 471
AR - Argentina 469
KR - Corea 462
TW - Taiwan 453
RU - Federazione Russa 397
PE - Perù 385
GR - Grecia 348
FI - Finlandia 347
CL - Cile 344
AU - Australia 342
UA - Ucraina 297
AT - Austria 276
TH - Thailandia 255
CH - Svizzera 246
BE - Belgio 236
EC - Ecuador 227
RO - Romania 199
SA - Arabia Saudita 191
IE - Irlanda 168
PK - Pakistan 167
DK - Danimarca 163
BD - Bangladesh 156
EG - Egitto 148
IR - Iran 142
IL - Israele 115
CZ - Repubblica Ceca 113
BG - Bulgaria 112
MA - Marocco 102
MY - Malesia 101
ZA - Sudafrica 99
HU - Ungheria 92
PH - Filippine 87
HR - Croazia 77
IQ - Iraq 71
SI - Slovenia 70
RS - Serbia 69
NZ - Nuova Zelanda 64
VE - Venezuela 64
TN - Tunisia 60
LT - Lituania 58
LB - Libano 55
NO - Norvegia 51
PA - Panama 49
LV - Lettonia 47
AE - Emirati Arabi Uniti 45
JO - Giordania 41
BO - Bolivia 40
KZ - Kazakistan 39
UY - Uruguay 39
CR - Costa Rica 37
SK - Slovacchia (Repubblica Slovacca) 36
GT - Guatemala 34
NG - Nigeria 33
DZ - Algeria 31
SN - Senegal 31
QA - Qatar 28
NP - Nepal 27
PY - Paraguay 27
LK - Sri Lanka 26
UZ - Uzbekistan 26
HN - Honduras 25
PS - Palestinian Territory 25
SY - Repubblica araba siriana 22
CY - Cipro 20
DO - Repubblica Dominicana 20
BY - Bielorussia 19
EE - Estonia 18
OM - Oman 18
ET - Etiopia 17
GE - Georgia 16
KE - Kenya 16
NI - Nicaragua 16
KW - Kuwait 13
PR - Porto Rico 13
AZ - Azerbaigian 12
MO - Macao, regione amministrativa speciale della Cina 12
AL - Albania 11
BA - Bosnia-Erzegovina 11
RE - Reunion 11
Totale 62.206
Salva come PNG Salva come JPEG
Città #
Ashburn 9.089
Warsaw 1.694
Germantown 1.013
Singapore 980
Woodbridge 644
Fairfield 617
Milan 605
Trieste 581
Beijing 578
Rome 555
Chandler 552
Ann Arbor 531
São Paulo 520
San Jose 481
Munich 460
Dallas 454
Houston 433
Madrid 411
Hong Kong 395
Shanghai 366
Guangzhou 342
Tokyo 323
Los Angeles 320
Wilmington 311
Istanbul 305
Seattle 284
Jacksonville 262
Ho Chi Minh City 258
Lima 251
Rio de Janeiro 250
Barcelona 249
Paris 245
New York 243
Chicago 241
Cambridge 227
Frankfurt am Main 224
Seoul 213
Bogotá 211
Hanoi 203
Hangzhou 201
Helsinki 195
Hefei 186
Buenos Aires 184
Athens 182
Taipei 180
Santiago 179
Jakarta 170
Lisbon 168
Vienna 167
Ankara 157
Council Bluffs 154
Montréal 151
Naples 151
Dublin 149
Princeton 149
Chengdu 145
Mcallen 143
Amsterdam 142
Moscow 142
Bangkok 139
Turin 139
Bologna 138
Florence 136
Bengaluru 132
London 126
Izmir 121
The Dalles 117
Curitiba 112
Toronto 112
Brasília 110
Chennai 109
Mumbai 107
Nanjing 107
Medellín 106
Berlin 105
Columbus 103
Melbourne 103
Boardman 102
Valencia 102
Hyderabad 100
Montreal 97
Brussels 96
Las Vegas 95
Quito 95
Sydney 95
Zurich 95
Sofia 94
Wuhan 92
Washington 90
Belo Horizonte 88
Copenhagen 88
Guadalajara 87
Thessaloniki 87
Goiânia 86
Porto 86
Porto Alegre 86
Benito Juarez 85
Lauterbourg 84
Boston 81
Mexico City 79
Totale 33.428
Salva come PNG Salva come JPEG
Nome #
Bispecific antibodies targeting tumor-associated antigens and neutralizing complement regulators increase the efficacy of antibody-based immunotherapy in mice. 44.770
Pathogenic role of complement in antiphospholipid syndrome and therapeutic implications 772
Meniscal ossicles as micro-CT imaging biomarker in a rodent model of antigen-induced arthritis: A synchrotron-based x-ray pilot study 456
Targeted tumor imaging of anti-CD20-polymeric nanoparticles developed for the diagnosis of B-cell malignancies 446
Targeted delivery of neutralizing anti-C5 antibody to renal endothelium prevents complement- dependent tissue damage 412
NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: Evidence for a NOTCH1 mutation-driven epigenetic dysregulation 403
Antiphospholipid antibodies detected by line immunoassay differentiate among patients with antiphospholipid syndrome, with infections and asymptomatic carriers 397
Invasive meningococcal disease in three siblings with hereditary deficiency of the 8th component of complement: Evidence for the importance of an early diagnosis 348
Mutations in the 3' untranslated region (3' UTR) of NOTCH1 are associated with low CD20 expression levels in chronic lymphocytic leukemia 345
Targeting CD34+ cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis 343
A non-complement-fixing antibody to  2 glycoprotein I as a novel therapy for antiphospholipid syndrome 339
New insight into antiphospholipid syndrome: antibodies to β2glycoprotein I-domain 5 fail to induce thrombi in rats 322
Complement as a biological tool to control tumor growth 316
Selective therapeutic control of C5a and the terminal complement complex by anti-C5 single-chain Fv in an experimental model of antigen-induced arthritis in rats. 315
New Potential Therapeutic Approach for the Treatment of B-Cell Malignancies Using Chlorambucil/Hydroxychloroquine-Loaded Anti-CD20 Nanoparticles. 304
A new approach for the treatment of CLL using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles 282
Targeted nanoparticles and complement activation 282
An update on the xenograft and mouse models suitable for investigating new therapeutic compounds for the treatment of B-cell malignancies. 266
Complement activation in antiphospholipid syndrome and its inhibition to prevent rethrombosis after arterial surgery 258
Critical role and therapeutic control of the lectin pathway of complement activation in an abortion-prone mouse mating 257
Diagnostic and prognostic role of eEF1A in chronic lymphocytic leukaemia 248
A Human Monoclonal Antibody Against Domain I Of beta 2-Glycoprotein I prevents Clotting and Fetal Loss Induced By Polyclonal Anti-Phospholipid Antibodies In Animal Models. 243
Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59 231
Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5 227
Complement as effector system in cancer immunotherapy. 224
Alterations in trabecular bone μ-architecture and cartilages in rats with antigen-induced arthritis (AIA) resulting from synchrotron-based X-ray imaging analysis 224
Complement C1q and C8beta deficiency in an individual with recurrent bacterial meningitis and adult-onset systemic lupus erythematosus-like illness. 223
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab. 222
High fecal calprotectin levels are associated with SARS-CoV-2 intestinal shedding in COVID-19 patients: A proof-of-concept study 221
Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma. 218
Effects of eEF1A1 targeting by aptamer/siRNA in chronic lymphocytic leukaemia cells 216
The seventh complement component is expressed on endothelial cells membrane and exerts an anti-inflammatory action 214
The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target 199
Cubosomes for in vivo fluorescence lifetime imaging 199
OP0023 Targeted Polymeric Nanoparticles as Diagnostic and Therapeutic Tool for Rheumatoid Arthritis 195
Treatment of experimental arthritis by targeting synovial endothelium with a neutralizing recombinant antibody to C5. 193
Dynamics of complement activation in aHUS and how to monitor eculizumab therapy 193
Consumption of complement in a 26-year-old woman with severe thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination 193
Complement in human diseases: Lessons from complement deficiencies. 188
Effects of chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles on a human/mouse model of Burkitt lymphoma 186
Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. 184
Multiple-Organ Complement Deposition on Vascular Endothelium in COVID-19 Patients 178
DEVELOPMENT OF CHLORAMBUCIL/HYDROXYCHLOROQUINE-LOADED ANTI-CD20 NANOPARTICLES FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA : IN VITRO MODEL 177
Detection of mRNA for the terminal complement components C5, C6, C8 and C9 in human umbilical vein endothelial cells in vitro. 176
Biological Features of Nanoparticles: Protein Corona Formation and Interaction with the Immune System 175
Exploratory study on the effects of biodegradable nanoparticles with drugs on malignant B cells and on a human/mouse model of Burkitt lymphoma. 175
Nanoparticles-based oligonucleotides delivery in cancer: Role of zebrafish as animal model 170
FRI0030 Anti-TNF-α Antibody Targeted To Inflamed Synovial Tissue for The Treatment of Rheumatoid Arthritis 168
A novel complement-fixing IgM antibody targeting GPC1 as a useful immunotherapeutic strategy for the treatment of pancreatic ductal adenocarcinoma 167
null 166
P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma. 165
Posttransplant ischemia-reperfusion injury in transplanted heart is prevented by a minibody to the fifth component of complement. 163
Complement Activation and Thrombin Generation by MBL Bound to β2-Glycoprotein I 163
Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity. 161
High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids 161
C7 is expressed on endothelial cells as a trap for the assembling terminal complement complex and may exert anti-inflammatory function. 160
Constitutive psgl-1 correlates with cd30 and tcr pathways and represents a potential target for immunotherapy in anaplastic large t-cell lymphoma 159
Humoral immunotherapy of multiple myeloma: perspectives and perplexities. 158
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 156
The cleavage site of C5 from man and animals as a common target for neutralizing human monoclonal antibodies: in vitro and in vivo studies 150
In vivo biodistribution and lifetime analysis of cy5.5-conjugated rituximab in mice bearing lymphoid tumor xenograft using time-domain near-infrared optical imaging. 150
The development of atypical hemolytic uremic syndrome depends on complement C5. 148
Cubosomes stabilized by a polyphosphoester-analog of Pluronic F127 with reduced cytotoxicity 148
The anti-glypican 1 AT101 antibody as targeting agent to effectively deliver chitosan nanobubbles to glioblastoma cells. 147
DNA-loaded targeted nanoparticles as a safe platform to produce exogenous proteins in tumor B cells 146
Zebrafish: A Useful Animal Model for the Characterization of Drug-Loaded Polymeric NPs 145
Simple scale-up of recombinant antibody production using an UCOE containing vector 143
The Inflammatory Feed-Forward Loop Triggered by the Complement Component C3 as a Potential Target in Endometriosis 143
Idarubicin-loaded chitosan nanobubbles to improve survival and decrease drug side effects in hepatocellular carcinoma 140
An allosteric redox switch in domain V of β2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition 139
Stealth-Engineered Albumin-Coated Nanoparticles for Targeted Therapy: Effective Drug Delivery and Tumor Suppression in Xenograft-Zebrafish Model 139
Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. 138
Phage Display Technology for Human Monoclonal AntibodiesHuman Monoclonal Antibodies 136
Plasminogen activator-coated nanobubbles targeting cell-bound β2-glycoprotein I as a novel thrombus-specific thrombolytic strategy 134
Complement system and phagocytosis in a colonial protochordate 124
Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies 122
The terminal complement pathway is activated in septic but not in aseptic shoulder revision arthroplasties 122
The proline-rich antimicrobial peptide B7-005: low bacterial resistance, safe for human cells and effective in zebrafish embryo bacteraemia model 120
null 117
Antiphospholipid IgG Certified Reference Material ERM®-DA477/IFCC: a tool for aPL harmonization? 116
The Proteoglycan Glypican-1 as a Possible Candidate for Innovative Targeted Therapeutic Strategies for Pancreatic Ductal Adenocarcinoma 113
The J-elongated conformation of b2-glycoprotein I predominates in solution: implications for our understanding of antiphospholipid syndrome 112
β2GPI-targeted polymeric nanoparticles form a protective layer to prevent vascular thrombosis in an anti-phospholipid syndrome model 111
null 105
Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab 105
Markers of complement activation in plasma during quiescent phases in patients with catastrophic antiphospholipid syndrome 105
Novel Nanotechnology Approaches to Overcome Drug Resistance in the Treatment of Hepatocellular Carcinoma: Glypican 3 as a Useful Target for Innovative Therapies 92
Evidence of a Lytic Pathway in an Invertebrate Complement System: Identification of a Terminal Complement Complex Gene in a Colonial Tunicate and Its Evolutionary Implications 77
Hereditary deficiency of the second component of complement: Early diagnosis and 21-year follow-up of a family 75
Surface antibody changes protein corona both in human and mouse serum but not final opsonization and elimination of targeted polymeric nanoparticles 9
Mechanistic Divergence and Differential Antibacterial Potency of the Proline-Rich Antimicrobial Peptide B7-005 Across ESKAPE + E Pathogens 8
Targeted chitosan nanobubbles as a strategy to down-regulate microRNA-17 into B-cell lymphoma models 7
Totale 62.858
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.234
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.234
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021137 0 0 0 0 0 0 0 0 0 0 0 137
2021/20221.026 98 75 74 88 21 69 38 36 130 100 55 242
2022/20231.515 132 232 125 238 92 258 32 152 178 16 45 15
2023/2024893 56 49 52 37 111 123 135 170 16 28 78 38
2024/202520.733 23 73 113 154 191 254 231 197 344 273 5.943 12.937
2025/202632.003 5.814 4.889 5.742 5.334 5.130 2.254 758 180 712 736 310 144
Totale 62.858